April 2014
Volume 55, Issue 13
Jump To...
Free
ARVO Annual Meeting Abstract  |   April 2014
Heidelberg Retina Topograph Topographic Change Analysis in Progressing and Stable Eyes
Jagannath Nayak; Christopher Bowd; Felipe A Medeiros; Robert N Weinreb; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill
Author Affiliations & Notes
  • Jagannath Nayak
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Christopher Bowd
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Felipe A Medeiros
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Robert N Weinreb
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Jeffrey M Liebmann
    New York University School of Medicine, New York, NY
    Department of Ophthalmology, Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Christopher A Girkin
    School of Medicine, University of Alabama, Birmingham, AL
  • Linda M Zangwill
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships Jagannath Nayak, None; Christopher Bowd, None; Felipe Medeiros, Alcon Laboratories Inc. (F), Alcon Laboratories Inc. (R), Allergan Inc. (F), Allergan Inc. (R), Allergan, Inc. (C), Bausch & Lomb (F), Carl Zeiss Meditec Inc. (F), Carl Zeiss Meditec Inc. (R), Carl-Zeiss Meditec, Inc (C), Merck Inc. (F), National Eye Institute (F), Novartis (C), Reichert Inc. (R), Reichert, Inc. (F), Sensimed (F), Topcon, Inc. (F); Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Bausch&Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Genentech (F), Heidelberg Engineering GmbH (F), National Eye Institute (F), Nidek (F), Novartis (F), Optovue (F), Sensimed (C), Topcon (C), Topcon (F); Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Allergan, Inc. (F), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc. (F), Diopysis, inc. (C), Diopysis, inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Phamaceuticals, Inc. (C), Optovue, inc (F), Quark Pharmaceuticals, Inc. (F), Reichert, Inc. (F), Sensimed, Inc. (F), Topcon, Inc. (F), Valeant Pharmaceutiicals, Inc. (C); Christopher Girkin, Carl Zeiss Meditech, Inc. (F), Heidelberg Engineering, GmbH (F), SOLX (F); Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), Nidek Inc (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 983. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Heidelberg Retina Topograph Topographic Change Analysis in Progressing and Stable Eyes
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Jagannath Nayak, Christopher Bowd, Felipe A Medeiros, Robert N Weinreb, Jeffrey M Liebmann, Christopher A Girkin, Linda M Zangwill; Heidelberg Retina Topograph Topographic Change Analysis in Progressing and Stable Eyes. Invest. Ophthalmol. Vis. Sci. 2014;55(13):983.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract
 
Purpose
 

To describe the performance, in an independent population, of previously published confocal scanning laser ophthalmoscopy Topographic Change Analysis (TCA) parameter cut-offs for discriminating between progressing glaucoma and stable eyes.

 
Methods
 

Five published TCA cut-offs (Bowd et al., IOVS, 2009; Chauhan et al., IOVS, 2009) were applied to the following 4 groups: 54 eyes progressing by optic disc stereophotograph assessment (average follow-up time = 7.93, SD = 1.29 years), 81 eyes progressing by standard automated perimetry guided progression analysis (GPA) (5.20, SD = 2.55 years), 72 stable glaucoma eyes (patients tested 5 times over 5 weeks), and 135 healthy eyes (5.05, SD = 2.03 years). All eyes were imaged at least four times by HRT (Heidelberg Engineering, Inc.) as part of the Diagnostic Innovations in Glaucoma Study (DIGS) and African Descent and Glaucoma Evaluation Study (ADAGES). Sensitivity and specificity for classifying progressed and stable eyes were reported.

 
Results
 

The two TCA parameters providing the best sensitivity/specificity trade-off were the 95% cut-off for the largest clustered super-pixel area within the optic disc margin (Bowd et al.) and the Moderate Criteria (largest clustered superpixel area within the optic disc margin ≥1% of the disc area with ≥50 µm mean depth change) (Chauhan et al.) (see Table). These cut-offs detected progression over a similar time frame. Specificity in healthy eyes was lower than in stable glaucoma eyes.

 
Conclusions
 

The performance of published TCA parameter cut-offs varies, as expected. Low specificity of TCA in healthy eyes might be due to the effects of aging on optic disc topography, evidenced by the long follow-up in this group. Confirmation of TCA changes in another group of healthy eyes is needed to determine whether this is the case.

 
Image not available
View OriginalDownload Slide
Image not available
View OriginalDownload Slide
 
Keywords: 550 imaging/image analysis: clinical • 733 topography • 627 optic disc  
© 2014, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept